{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:21Z","timestamp":1792788741307,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Mayo Clinic Women's Health Research Center","id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["U54-DK083908"],"award-info":[{"award-number":["U54-DK083908"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["F32-DK128987"],"award-info":[{"award-number":["F32-DK128987"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["T32-DK07013"],"award-info":[{"award-number":["T32-DK07013"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["R01-DK128844\/S3"],"award-info":[{"award-number":["R01-DK128844\/S3"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,5]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Fibroblast growth factor 23 and 24,25-dihydroxyvitamin D are positively correlated and are significantly lower in Dent disease than in idiopathic calcium kidney stones patients.<\/jats:p>\n <\/jats:list-item>\n \n Dent patients with low 24,25-dihydroxyvitamin D had greater hypercalciuria and proteinuria, and, among adults, higher 1,25-dihydroxyvitamin D concentrations.<\/jats:p>\n <\/jats:list-item>\n \n Moderate phosphate supplementation mitigates hypercalciuria.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Hypercalciuria is a prominent characteristic in Dent disease type 1 (DD1) and is associated with kidney stones and nephrocalcinosis. The objectives of this study were to assess fibroblast growth factor 23 (FGF23) and 24,25-dihydroxyvitamin D (24,25(OH)\n 2<\/jats:sub>\n D) in DD1 patients and investigate the effects of phosphate supplementation on urinary calcium excretion.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Serum and 24-hour urine assessments from adult and pediatric DD1 patients (\n N<\/jats:italic>\n =10 adults;\n N<\/jats:italic>\n =9 pediatrics) were compared with adult control subjects with a history of idiopathic calcium kidney stones and hypercalciuria (\n N<\/jats:italic>\n =9). Adult DD1 patients and control participants completed an oral phosphate supplementation intervention (1 g\/d\u00d714 days) with reassessment immediately after intervention.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n FGF23 was significantly lower in DD1 than in the control cohort (adults,\n P<\/jats:italic>\n = 0.006) and positively correlated with 24,25(OH)\n 2<\/jats:sub>\n D across all study cohorts. The concentrations of 24,25(OH)\n 2<\/jats:sub>\n D were low with conversion ratios (25-hydroxyvitamin D: 24,25(OH)\n 2<\/jats:sub>\n D) exceeding the clinical reference limit for five of 10 adults and six of 9 pediatric DD1 patients. The DD1 cohorts were then stratified by the 24,25(OH)\n 2<\/jats:sub>\n D ratio into \u201cnormal\u201d and \u201clow\u201d 24,25(OH)\n 2<\/jats:sub>\n D. Adult DD1 patients with low 24,25(OH)\n 2<\/jats:sub>\n D (\n n<\/jats:italic>\n =5) had lower FGF23, higher 1,25-dihydroxyvitamin D, greater urine calcium, and greater urine protein. Pediatric stratified data mirrored that in adults with the exception of no difference in serum 1,25-dihydroxyvitamin D. Phosphate supplementation was effective in decreasing urine calcium in both adult DD1 and control adult cohorts.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Clinical measurement of 24,25(OH)\n 2<\/jats:sub>\n D is a novel and useful analysis for evaluating the severity of calcium and protein dysregulation in DD1. In addition, moderate phosphate supplementation effectively mitigates urine calcium excretion in DD1 adult patients.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n ClinicalTrials.gov, NCT02016235.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000978","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:00:50Z","timestamp":1772211650000},"page":"811-821","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-6122","authenticated-orcid":false,"given":"Carmen J.","family":"Reynolds","sequence":"first","affiliation":[{"name":"Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4363-2547","authenticated-orcid":false,"given":"Zejfa","family":"Haskic","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1536-0582","authenticated-orcid":false,"given":"Barbara M.","family":"Seide","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-7835","authenticated-orcid":false,"given":"Michael F.","family":"Romero","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota"},{"name":"Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9215-1273","authenticated-orcid":false,"given":"David S.","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"New York Harbor VA Healthcare System, New York, New York"},{"name":"NYU Langone Health, New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-5944","authenticated-orcid":false,"given":"John C.","family":"Lieske","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-6722","authenticated-orcid":false,"given":"Lada","family":"Beara-Lasic","sequence":"additional","affiliation":[{"name":"New York Harbor VA Healthcare System, New York, New York"},{"name":"NYU Langone Health, New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"4","key":"B1-20261023","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41581-021-00513-4","article-title":"The genetics of kidney stone disease and nephrocalcinosis","volume":"18","author":"Singh","year":"2022","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"B2-20261023","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ekir.2023.03.012","article-title":"The site and type of CLCN5 genetic variation impact the resulting dent disease-1 phenotype","volume":"8","author":"Arnous","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"10","key":"B3-20261023","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1093\/ndt\/gfl346","article-title":"Recent advances in understanding the clinical and genetic heterogeneity of Dent's disease","volume":"21","author":"Ludwig","year":"2006","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B4-20261023","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/hmg\/8.2.247","article-title":"Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease","volume":"8","author":"Devuyst","year":"1999","journal-title":"Hum Mol Genet."},{"issue":"1","key":"B5-20261023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5527\/wjn.v6.i1.14","article-title":"Functional coupling of V-ATPase and ClC-5","volume":"6","author":"Satoh","year":"2017","journal-title":"World J Nephrol."},{"issue":"6","key":"B6-20261023","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1074\/jbc.RA119.011366","article-title":"Cl- and H+ coupling properties and subcellular localizations of wildtype and disease-associated variants of the voltagegated Cl-\/H+ exchanger ClC-5","volume":"295","author":"Chang","year":"2020","journal-title":"J Biol Chem."},{"issue":"4","key":"B7-20261023","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1681\/ASN.0000000000000084","article-title":"Impaired endosome maturation mediates tubular proteinuria in Dent disease cell culture and mouse models","volume":"34","author":"Shipman","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"39","key":"B8-20261023","doi-asserted-by":"crossref","first-page":"14467","DOI":"10.1074\/jbc.RA119.010173","article-title":"A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues","volume":"294","author":"Meyer","year":"2019","journal-title":"J Biol Chem."},{"issue":"11","key":"B9-20261023","doi-asserted-by":"crossref","first-page":"102559","DOI":"10.1016\/j.jbc.2022.102559","article-title":"Rapid genomic changes by mineralotropic hormones and kinase SIK inhibition drive coordinated renal Cyp27b1 and Cyp24a1 expression via CREB modules","volume":"298","author":"Meyer","year":"2022","journal-title":"J Biol Chem."},{"issue":"11","key":"B10-20261023","doi-asserted-by":"crossref","first-page":"bqae134","DOI":"10.1210\/endocr\/bqae134","article-title":"In vivo contribution of Cyp24a1 promoter vitamin D response elements","volume":"165","author":"Meyer","year":"2024","journal-title":"Endocrinology."},{"issue":"3","key":"B11-20261023","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"11","key":"B12-20261023","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1681\/ASN.2008121273","article-title":"Klotho prevents renal calcium loss","volume":"20","author":"Alexander","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B13-20261023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"issue":"3","key":"B14-20261023","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/embj.201284188","article-title":"FGF23 promotes renal calcium reabsorption through the TRPV5 channel","volume":"33","author":"Andrukhova","year":"2014","journal-title":"EMBO J."},{"issue":"1","key":"B15-20261023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.1998.00718.x","article-title":"X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations","volume":"53","author":"Scheinman","year":"1998","journal-title":"Kidney Int."},{"issue":"4","key":"B16-20261023","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1359\/jbmr.1997.12.4.598","article-title":"Three-fold induction of renal 25-hydroxyvitamin D3-24-hydroxylase activity and increased serum 24,25-dihydroxyvitamin D3 levels are correlated with the healing process after chick tibial fracture","volume":"12","author":"Seo","year":"1997","journal-title":"J Bone Miner Res."},{"issue":"1","key":"B17-20261023","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1373\/clinchem.2015.244459","article-title":"LC-MS\/MS for identifying patients with CYP24A1 mutations","volume":"62","author":"Ketha","year":"2016","journal-title":"Clin Chem."},{"issue":"12","key":"B18-20261023","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2215\/CJN.0000000817","article-title":"Genetic and clinical characterization of a large cohort with suspected monogenic stone disease","volume":"20","author":"Cogal","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B19-20261023","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1038\/s41598-022-15033-9","article-title":"The metabolism of 1,25(OH)2D3 in clinical and experimental kidney disease","volume":"12","author":"Turner","year":"2022","journal-title":"Sci Rep."},{"issue":"5","key":"B20-20261023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJMoa1103864","article-title":"Mutations in CYP24A1 and idiopathic infantile hypercalcemia","volume":"365","author":"Schlingmann","year":"2011","journal-title":"New Engl J Med."},{"issue":"7","key":"B21-20261023","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1210\/jc.2013-4388","article-title":"Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS\/MS involving derivatization with DMEQ-TAD","volume":"99","author":"Kaufmann","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"B22-20261023","doi-asserted-by":"crossref","first-page":"bvab119","DOI":"10.1210\/jendso\/bvab119","article-title":"24-hydroxylase deficiency due to CYP24A1 sequence variants: comparison with other vitamin D-mediated hypercalcemia disorders","volume":"5","author":"Azer","year":"2021","journal-title":"J Endocr Soc."},{"issue":"11","key":"B23-20261023","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00467-006-0217-0","article-title":"Long-term follow-up of patients with idiopathic infantile hypercalcaemia","volume":"21","author":"Huang","year":"2006","journal-title":"Pediatr Nephrol."},{"key":"B24-20261023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2015.06.018","article-title":"Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study","volume":"81","author":"Cools","year":"2015","journal-title":"Bone."},{"issue":"10","key":"B25-20261023","first-page":"593","article-title":"Idiopathic infantile hypercalcemia, presenting in adulthood-no longer idiopathic nor infantile: two case reports and review","volume":"79","author":"Tray","year":"2015","journal-title":"Conn Med."},{"key":"B26-20261023","doi-asserted-by":"crossref","first-page":"736240","DOI":"10.3389\/fendo.2021.736240","article-title":"Overlapping phenotypes associated with CYP24A1, SLC34A1, and SLC34A3 mutations: a cohort study of patients with hypersensitivity to vitamin D","volume":"12","author":"Molin","year":"2021","journal-title":"Front Endocrinol."},{"issue":"2","key":"B27-20261023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/8756-3282(85)90313-8","article-title":"Autoradiographic localization of 24R,25-dihydroxyvitamin D3 in epiphyseal cartilage","volume":"6","author":"Fine","year":"1985","journal-title":"Bone."},{"issue":"12","key":"B28-20261023","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/jbmr.5650091217","article-title":"Bone-forming ability of 24R,25-dihydroxyvitamin D in the hypophosphatemic mouse","volume":"9","author":"Yamate","year":"1994","journal-title":"J Bone Miner Res."},{"issue":"6","key":"B29-20261023","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1210\/endo.137.6.8641218","article-title":"24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice","volume":"137","author":"Ono","year":"1996","journal-title":"Endocrinology."},{"issue":"8","key":"B30-20261023","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI98093","article-title":"Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2","volume":"128","author":"Martineau","year":"2018","journal-title":"J Clin Invest."},{"key":"B31-20261023","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bone.2017.11.011","article-title":"The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: the cardiovascular health study","volume":"107","author":"Ginsberg","year":"2018","journal-title":"Bone."},{"issue":"11","key":"B32-20261023","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/clinchem\/hvad151","article-title":"Functional assessment of vitamin D status by a novel metabolic approach: the low vitamin D profile concept","volume":"69","author":"Herrmann","year":"2023","journal-title":"Clin Chem."},{"issue":"1","key":"B33-20261023","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI110023","article-title":"Impaired 24,25-dihydroxyvitamin D production in anephric human and pig","volume":"67","author":"Horst","year":"1981","journal-title":"J Clin Invest."},{"issue":"2","key":"B34-20261023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jcb.10341","article-title":"Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone","volume":"88","author":"Zierold","year":"2003","journal-title":"J Cell Biochem."},{"issue":"2","key":"B35-20261023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-21-0713","article-title":"Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review","volume":"186","author":"Cappellani","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"B36-20261023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mayocpiqo.2022.03.002","article-title":"Changes in serum intact fibroblast growth factor 23 concentrations from midlife to late life and their predictors in the community: the ARIC study","volume":"6","author":"Ishigami","year":"2022","journal-title":"Mayo Clinic Proc Innov Qual Outcomes."},{"issue":"1","key":"B37-20261023","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1515\/med-2021-0288","article-title":"Serum intact fibroblast growth factor 23 in healthy paediatric population","volume":"16","author":"Stanczyk","year":"2021","journal-title":"Open Med (Wars)."},{"issue":"11","key":"B38-20261023","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2215\/CJN.03130314","article-title":"Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD","volume":"9","author":"Stubbs","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B39-20261023","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2012.193","article-title":"The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease","volume":"82","author":"Bosworth","year":"2012","journal-title":"Kidney Int."},{"issue":"2","key":"B40-20261023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.ajkd.2014.02.015","article-title":"Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials","volume":"64","author":"De Boer","year":"2014","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B41-20261023","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/j.ajkd.2008.08.021","article-title":"Effect of hydrochlorothiazide on urinary calcium excretion in Dent disease: an uncontrolled trial","volume":"52","author":"Blanchard","year":"2008","journal-title":"Am J Kidney Dis."},{"issue":"12","key":"B42-20261023","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1097\/01.ASN.0000036869.82685.F6","article-title":"Responsiveness of hypercalciuria to thiazide in Dent\u2019s disease","volume":"13","author":"Raja","year":"2002","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B43-20261023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM197401242900401","article-title":"Successful treatment of recurrent nephrolithiasis (calcium stones) with cellulose phosphate","volume":"290","author":"Pak","year":"1974","journal-title":"New Engl J Med."},{"issue":"5","key":"B44-20261023","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/jcem-51-5-998","article-title":"Orthophosphate therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria","volume":"51","author":"Van Den Berg","year":"1980","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"B45-20261023","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(76)90170-4","article-title":"Recurrent nephrolithiasis: natural history and effect of phosphate therapy: a double-blind controlled study","volume":"61","author":"Ettinger","year":"1976","journal-title":"Am J Med."},{"issue":"2","key":"B47-20261023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/nu9020095","article-title":"Dietary sources of phosphorus among adults in the United States: results from NHANES 2001-2014","volume":"9","author":"McClure","year":"2017","journal-title":"Nutrients."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:00:50Z","timestamp":1792771250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000978","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-08-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}